Download PDF
Thromb Haemost 2022; 122(07): 1076-1084
DOI: 10.1055/a-1690-8897
Review Article

Proteomics in Thrombosis and Hemostasis

Natasha Letunica
1   Department of Haematology, Murdoch Children's Research Institute, Melbourne, Australia
,
Suelyn Van Den Helm
1   Department of Haematology, Murdoch Children's Research Institute, Melbourne, Australia
,
Conor McCafferty
1   Department of Haematology, Murdoch Children's Research Institute, Melbourne, Australia
2   Department of Paediatrics, The University of Melbourne, Melbourne, Australia
,
Ella Swaney
1   Department of Haematology, Murdoch Children's Research Institute, Melbourne, Australia
2   Department of Paediatrics, The University of Melbourne, Melbourne, Australia
,
Tengyi Cai
1   Department of Haematology, Murdoch Children's Research Institute, Melbourne, Australia
2   Department of Paediatrics, The University of Melbourne, Melbourne, Australia
,
Chantal Attard
1   Department of Haematology, Murdoch Children's Research Institute, Melbourne, Australia
2   Department of Paediatrics, The University of Melbourne, Melbourne, Australia
,
Vasiliki Karlaftis
1   Department of Haematology, Murdoch Children's Research Institute, Melbourne, Australia
2   Department of Paediatrics, The University of Melbourne, Melbourne, Australia
,
Paul Monagle
1   Department of Haematology, Murdoch Children's Research Institute, Melbourne, Australia
2   Department of Paediatrics, The University of Melbourne, Melbourne, Australia
3   Department of Clinical Haematology, Royal Children's Hospital, Melbourne, Australia
4   Kids Cancer Centre, Sydney Children's Hospital, Randwick, Australia
,
Vera Ignjatovic
1   Department of Haematology, Murdoch Children's Research Institute, Melbourne, Australia
2   Department of Paediatrics, The University of Melbourne, Melbourne, Australia
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Proteomics, the simultaneous study of all proteins in a given cell, tissue or organism, is an innovative approach used to identify novel markers for diagnosis, prognosis and the pathophysiological mechanisms associated with diseases. Proteomic methodologies have been used in a variety of contexts such as investigating changes in protein abundance that may occur with disease presence, the response to therapeutic treatments as well as the impacts of age on the plasma proteome.

Over the last decade, significant technological advancements in proteomic techniques have resulted in an increase in the use of proteomics in thrombosis and hemostasis research, particularly in order to identify relevant and novel clinical markers associated with bleeding and thrombosis. This mini-review explores the use of proteomics in the setting of thrombosis and hemostasis from 2010-2020, across five main domains (platelets, blood clot composition, stroke, venous thromboembolism, and therapeutics), as well as provides insights into key considerations for conducting proteomic studies.

Keywords

proteomics - thrombosis - hemostasis


Publication History

Received: 10 October 2021

Accepted: 03 November 2021

Accepted Manuscript online:
09 November 2021

Article published online:
29 December 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Aslam B, Basit M, Nisar MA, Khurshid M, Rasool MH. Proteomics: technologies and their applications. J Chromatogr Sci 2017; 55 (02) 182-196
    CrossrefPubMedGoogle Scholar
  • 2 Hanash S, Taguchi A. Application of proteomics to cancer early detection. Cancer J 2011; 17 (06) 423-428
    CrossrefPubMedGoogle Scholar
  • 3 Mebazaa A, Vanpoucke G, Thomas G. et al. Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. Eur Heart J 2012; 33 (18) 2317-2324
    CrossrefPubMedGoogle Scholar
  • 4 Penn AM, Bibok MB, Saly VK. et al; SpecTRA study group. Validation of a proteomic biomarker panel to diagnose minor-stroke and transient ischaemic attack: phase 2 of SpecTRA, a large scale translational study. Biomarkers 2018; 23 (08) 793-803
    CrossrefPubMedGoogle Scholar
  • 5 Stachowicz A, Zabczyk M, Natorska J. et al. Differences in plasma fibrin clot composition in patients with thrombotic antiphospholipid syndrome compared with venous thromboembolism. Sci Rep 2018; 8 (01) 17301
    CrossrefPubMedGoogle Scholar
  • 6 Periayah MH, Halim AS, Mat Saad AZ. Mechanism action of platelets and crucial blood coagulation pathways in hemostasis. Int J Hematol Oncol Stem Cell Res 2017; 11 (04) 319-327
    PubMedGoogle Scholar
  • 7 Azcona L, López Farré AJ, Jiménez Mateos-Cáceres P. et al. Impact of clopidogrel and aspirin treatment on the expression of proteins in platelets from type-2 diabetic patients with stable coronary ischemia. J Pharm Sci 2012; 101 (08) 2821-2832
    CrossrefPubMedGoogle Scholar
  • 8 Vélez P, Ocaranza-Sánchez R, López-Otero D. et al. 2D-DIGE-based proteomic analysis of intracoronary versus peripheral arterial blood platelets from acute myocardial infarction patients: upregulation of platelet activation biomarkers at the culprit site. Proteomics Clin Appl 2016; 10 (08) 851-858
    CrossrefPubMedGoogle Scholar
  • 9 McCafferty C, Van Den Helm S, Letunica N. et al. Increased platelet activation in SARS-CoV-2 infected non-hospitalised children and adults, and their household contacts. Br J Haematol 2021; 195 (01) 90-94
    CrossrefPubMedGoogle Scholar
  • 10 Bachmair E-M, Bots ML, Mennen LI. et al. Effect of supplementation with an 80:20 cis9,trans11 conjugated linoleic acid blend on the human platelet proteome. Mol Nutr Food Res 2012; 56 (07) 1148-1159
    CrossrefPubMedGoogle Scholar
  • 11 Alonso-Orgaz S, Moreno-Luna R, López JA. et al. Proteomic characterization of human coronary thrombus in patients with ST-segment elevation acute myocardial infarction. J Proteomics 2014; 109: 368-381
    CrossrefPubMedGoogle Scholar
  • 12 Schmitt LR, Henderson R, Barrett A. et al. Mass spectrometry-based molecular mapping of native FXIIIa cross-links in insoluble fibrin clots. J Biol Chem 2019; 294 (22) 8773-8778
    CrossrefPubMedGoogle Scholar
  • 13 Ząbczyk M, Stachowicz A, Natorska J, Olszanecki R, Wiśniewski JR, Undas A. Plasma fibrin clot proteomics in healthy subjects: relation to clot permeability and lysis time. J Proteomics 2019; 208: 103487
    CrossrefPubMedGoogle Scholar
  • 14 Bhagwat SR, Hajela K, Bhutada S. et al. Identification of unexplored substrates of the serine protease, thrombin, using N-terminomics strategy. Int J Biol Macromol 2020; 144: 449-459
    CrossrefPubMedGoogle Scholar
  • 15 ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost 2014; 12 (10) 1580-1590
    CrossrefPubMedGoogle Scholar
  • 16 Bruzelius M, Iglesias MJ, Hong M-G. et al. PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study. Blood 2016; 128 (23) e59-e66
    CrossrefPubMedGoogle Scholar
  • 17 Jensen SB, Hindberg K, Solomon T. et al. Discovery of novel plasma biomarkers for future incident venous thromboembolism by untargeted synchronous precursor selection mass spectrometry proteomics. J Thromb Haemost 2018; 16 (09) 1763-1774
    CrossrefPubMedGoogle Scholar
  • 18 Gorelick PB. The global burden of stroke: persistent and disabling. Lancet Neurol 2019; 18 (05) 417-418
    CrossrefPubMedGoogle Scholar
  • 19 Penn AM, Saly V, Trivedi A. et al. Differential proteomics for distinguishing ischemic stroke from controls: a pilot study of the SpecTRA project. Transl Stroke Res 2018; 9 (06) 590-599
    CrossrefPubMedGoogle Scholar
  • 20 O'Connell GC, Walsh KB, Burrage E, Adeoye O, Chantler PD, Barr TL. High-throughput profiling of the circulating proteome suggests sexually dimorphic corticosteroid signaling following ischemic stroke. Physiol Genomics 2018; 50 (10) 876-883
    CrossrefPubMedGoogle Scholar
  • 21 Thiele T, Steil L, Völker U, Greinacher A. Proteomics of blood-based therapeutics: a promising tool for quality assurance in transfusion medicine. BioDrugs 2007; 21 (03) 179-193
    CrossrefPubMedGoogle Scholar
  • 22 Timperio AM, Gevi F, Grazzini G, Vaglio S, Zolla L. Comparison among plasma-derived clotting factor VIII by using monodimensional gel electrophoresis and mass spectrometry. Blood Transfus 2010; 8 (Suppl. 03) s98-s104
    PubMedGoogle Scholar
  • 23 Kimchi-Sarfaty C, Schiller T, Hamasaki-Katagiri N, Khan MA, Yanover C, Sauna ZE. Building better drugs: developing and regulating engineered therapeutic proteins. Trends Pharmacol Sci 2013; 34 (10) 534-548
    CrossrefPubMedGoogle Scholar
  • 24 Duarte TT, Spencer CT. Personalized proteomics: the future of precision medicine. Proteomes 2016; 4 (04) 29
    CrossrefPubMedGoogle Scholar
  • 25 Clarke W, Zhang Z, Chan DW. The application of clinical proteomics to cancer and other diseases. Clin Chem Lab Med 2003; 41 (12) 1562-1570
    CrossrefPubMedGoogle Scholar
  • 26 Ignjatovic V, Geyer PE, Palaniappan KK. et al. Mass spectrometry-based plasma proteomics: considerations from sample collection to achieving translational data. J Proteome Res 2019; 18 (12) 4085-4097
    CrossrefPubMedGoogle Scholar
  • 27 Deutsch EW, Omenn GS, Sun Z. et al. Advances and utility of the human plasma proteome. J Proteome Res 2021; 20 (12) 5241-5263
    CrossrefPubMedGoogle Scholar
  • 28 Geyer PE, Holdt LM, Teupser D, Mann M. Revisiting biomarker discovery by plasma proteomics. Mol Syst Biol 2017; 13 (09) 942
    CrossrefPubMedGoogle Scholar
  • 29 Messner CB, Demichev V, Bloomfield N. et al. Ultra-fast proteomics with Scanning SWATH. Nat Biotechnol 2021; 39 (07) 846-854
    CrossrefPubMedGoogle Scholar